Quick Answer
Imunon, Inc. reported Total Revenue of $500.0 thousand for fiscal year 2022.
Imunon, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $500.0K +0.0% |
$500.0K +0.0% |
$500.0K +0.0% |
| Revenue (ASC 606) | — | — | — | $500.0K +0.0% |
$500.0K +0.0% |
$500.0K +0.0% |
| Net Income | -$14.50M +22.2% |
-$18.62M +4.6% |
-$19.51M +45.6% |
-$35.90M -72.8% |
-$20.77M +3.3% |
-$21.48M -27.5% |
| Diluted EPS | -$6.83 +59.7% |
-$16.94 -684.3% |
-$2.16 +57.1% |
-$5.03 | — | — |
| Total Assets | $12.29M +26.5% |
$9.72M -55.7% |
$21.92M -50.2% |
$43.98M -40.6% |
$74.05M +97.3% |
$37.53M -2.0% |
| Cash and Equivalents | $8.78M +49.5% |
$5.87M +0.6% |
$5.84M -49.2% |
$11.49M -41.3% |
$19.59M +14.1% |
$17.16M +149.7% |
| Stockholders Equity | $7.06M +66.4% |
$4.24M -68.3% |
$13.39M -54.4% |
$29.33M -47.4% |
$55.80M +199.8% |
$18.61M +27.8% |
| R&D Expense | $7.78M -33.2% |
$11.64M +3.1% |
$11.29M -3.8% |
$11.73M +10.5% |
$10.62M -6.4% |
$11.34M -13.2% |
| Operating Income | -$14.65M +23.4% |
-$19.13M +9.0% |
-$21.03M +15.6% |
-$24.92M -18.6% |
-$21.01M -13.6% |
-$18.49M +10.1% |
| Shares Outstanding | 15 -100.0% |
966,712 -89.7% |
9.40M -89.1% |
86.56M +1400.0% |
5.77M +112.7% |
2.71M -88.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2022 | $125.0K | +0.0% | +0.0% |
| Revenue (ASC 606) | September 30, 2022 | $125.0K | +0.0% | +0.0% |
| Net Income | September 30, 2025 | -$3.43M | +29.2% | -25.1% |
| Diluted EPS | September 30, 2025 | -$1.16 | +69.1% | +46.0% |
| Total Assets | September 30, 2025 | $8.99M | -37.5% | +2.3% |
| Cash and Equivalents | September 30, 2025 | $5.25M | -49.1% | +11.0% |
| Stockholders Equity | September 30, 2025 | $4.08M | -50.2% | +53.5% |
| R&D Expense | September 30, 2025 | $1.90M | -42.3% | +54.8% |
| Operating Income | September 30, 2025 | -$3.48M | +29.9% | -25.6% |
| Shares Outstanding | September 30, 2025 | 2.90M | -80.0% | +19308386.7% |
- Imunon, Inc. reported Total Revenue of $500.0 thousand for fiscal year 2022.
- Imunon, Inc. showed an increase of +0.0% in Total Revenue compared to the prior fiscal year.
- Imunon, Inc. reported Revenue (ASC 606) of $500.0 thousand for fiscal year 2022.
- Imunon, Inc. showed an increase of +0.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Imunon, Inc. reported Net Income of -$14.50 million for fiscal year 2025.
- Imunon, Inc. showed an increase of +22.2% in Net Income compared to the prior fiscal year.
- Imunon, Inc. reported Diluted EPS of $6.83 per share (loss) for fiscal year 2025.
- Imunon, Inc. showed an increase of +59.7% in Diluted EPS compared to the prior fiscal year.
- Imunon, Inc. reported Total Assets of $12.29 million for fiscal year 2025.
- Imunon, Inc. showed an increase of +26.5% in Total Assets compared to the prior fiscal year.
- Imunon, Inc. reported Cash and Equivalents of $8.78 million for fiscal year 2025.
- Imunon, Inc. showed an increase of +49.5% in Cash and Equivalents compared to the prior fiscal year.
- Imunon, Inc. reported Stockholders Equity of $7.06 million for fiscal year 2025.
- Imunon, Inc. showed an increase of +66.4% in Stockholders Equity compared to the prior fiscal year.
- Imunon, Inc. reported R&D Expense of $7.78 million for fiscal year 2025.
- Imunon, Inc. showed a decrease of -33.2% in R&D Expense compared to the prior fiscal year.
- Imunon, Inc. reported Operating Income of -$14.65 million for fiscal year 2025.
- Imunon, Inc. showed an increase of +23.4% in Operating Income compared to the prior fiscal year.
- Imunon, Inc. reported Shares Outstanding of 3.42 million shares for fiscal year 2025.
- Imunon, Inc. showed an increase of +22797566.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: